Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI chatbot aims to curb drinking in liver disease patients

NCT ID NCT07450144

First seen Mar 06, 2026 · Last updated Jun 09, 2026 · Updated 17 times

Summary

This study tests whether a chatbot powered by large language models can help people with metabolic alcohol-related liver disease (MetALD) reduce their alcohol intake. About 50 adults in Hong Kong will use the chatbot for counseling. The main goal is to see if the approach is practical and acceptable, not yet to prove it works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Hong Kong Queen Mary Hospital

    RECRUITING

    Hong Kong, Hong Kong

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

Fibrosis metabolic dysfunction and alcohol associated liver disease metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.